Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 557 results for women's health

  1. Mental health of adults in contact with the criminal justice system (NG66)

    This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

  2. Skin cancer prevention (PH32)

    This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.

  3. Borderline personality disorder: recognition and management (CG78)

    This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.

  4. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  5. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

  6. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

  7. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)

    Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.

  8. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

  9. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  10. Pregnancy and neonates: mental health at booking appointment (IND63)

    This indicator covers proportion of pregnant women who were asked about their mental health at their first booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG82

  11. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  12. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  13. Contraception: advice for people with bipolar, schizophrenia or other psychoses (IND124)

    This indicator covers the percentage of women with schizophrenia, bipolar affective disorder or other psychoses under the age of 45 years who have been given information and advice in the previous 12 months about pregnancy, conception or contraception tailored to their pregnancy and contraceptive intentions. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM78

  14. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

  15. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.